Finnish Institute for Health and Welfare, later referred to as THL or Customer, request your tender for Various pharmaceutical products to the rescEU project. The Scope of procurement is described in more detail in Annex 1. The procurement is divided in fifteen (15) lots. Each product constitutes a separate lot. Tender may be submitted for one or several lots. - LOT 1: Morphine 10-20 mg/ml (1-5 ml per vial/ampoule, i.m., ATC N02AA01) - LOT 2: Ondansetron 2 mg/ml (2-4 ml per vial/ampoule, i.m. and i.v., ATC A04AA01) - LOT 3: Ondansetron 4-8 mg per tablet/capsule, oral (ATC A04AA01) - LOT 4: Hydrocortisone 250 mg / 2 ml (2 ml per vial/ampoule i.v., ATC H02AB09) - LOT 5: Epinephrine (Adrenaline) 1 mg/ml (1-5 ml per vial/ampoule, i.v. and i.m., ATC C01CA24) - LOT 6: Diazepam 10 mg / 2 ml (2 ml per vial/ampoule, i.m. and i.v., ATC N05BA01) - LOT 7: Midazolam 1-5 mg/ml (3-10 ml per vial/ampoule, i.v., ATC N05CD08) - LOT 8: Salbutamol 200 µg/dose (inhaler, 60 or 200 doses, ATC R03AC02) - LOT 9: Budesonide 0,5 mg/ml (2 ml nebuliser suspension per respule, ATC R03BA02) - LOT 10: Ciprofloxacin 2 mg/ml (100-200 ml per vial/ampoule, i.v., ATC J01MA02) - LOT 11: Streptomycin 1 g per vial/ampoule, i.m. (ATC J01GA01) - LOT 12: Meropenem 500-1000 mg per vial/ampoule, i.v. (ATC J01DH02) - LOT 13: Clindamycin 600 mg / 4 ml (4 ml per vial/ampoule, i.m. and i.v., ATC J01FF01) - LOT 14: Ciprofloxacin 250-500 mg per tablet/capsule, oral (ATC J01MA02) - LOT 15: Ethanol 95-96 % (5-20 ml per vial/ampoule, i.v., ATC V03AB16) The minimum requirements for the products is described in Annex 1.1. The Contract will be awarded to one Supplier for each lot based on a comparison of tenders. Tender that is economically the most advantageous will win the competition. The contract period shall enter into force once the contract has been signed by Contracting parties and expires when all contractual duties of the Contract have been performed. Estimated quantity for the products is described in Annex 6 (restricted to security classification level IV, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Supplier is not obliged to deliver the products under the Option. Please note that all times given in the Call for tenders refer to local time in Finland. Call for tenders, Annexes: Annex 1 Scope of the procurement Annex 1.1 Minimum requirements Annex 2 Contract Annex 3 Security annex Annex 4 JYSE 2014 SUPPLIES (updated version of April 2022) Annex 5 Confidentiality commitment Annex 6 Estimated quantity (restricted, TL IV) Please note that the numbering of the annexes differs between the Contract and the Call for tenders.
Määräaika
Tarjousten vastaanottamisen määräaika oli 2024-04-26.
Hankinta julkaistiin 2024-03-22.
hankintailmoitus (2024-03-22) Kohde Hankinnan laajuus
Otsikko: Various pharmaceutical products / 2024-2025
Viitenumero: THL/1198/2.02.06/2024
Lyhyt kuvaus:
“Finnish Institute for Health and Welfare, later referred to as THL or Customer, request your tender for Various pharmaceutical products to the rescEU...”
Lyhyt kuvaus
Finnish Institute for Health and Welfare, later referred to as THL or Customer, request your tender for Various pharmaceutical products to the rescEU project. The Scope of procurement is described in more detail in Annex 1.
The procurement is divided in fifteen (15) lots. Each product constitutes a separate lot. Tender may be submitted for one or several lots.
- LOT 1: Morphine 10-20 mg/ml (1-5 ml per vial/ampoule, i.m., ATC N02AA01)
- LOT 2: Ondansetron 2 mg/ml (2-4 ml per vial/ampoule, i.m. and i.v., ATC A04AA01)
- LOT 3: Ondansetron 4-8 mg per tablet/capsule, oral (ATC A04AA01)
- LOT 4: Hydrocortisone 250 mg / 2 ml (2 ml per vial/ampoule i.v., ATC H02AB09)
- LOT 5: Epinephrine (Adrenaline) 1 mg/ml (1-5 ml per vial/ampoule, i.v. and i.m., ATC C01CA24)
- LOT 6: Diazepam 10 mg / 2 ml (2 ml per vial/ampoule, i.m. and i.v., ATC N05BA01)
- LOT 7: Midazolam 1-5 mg/ml (3-10 ml per vial/ampoule, i.v., ATC N05CD08)
- LOT 8: Salbutamol 200 µg/dose (inhaler, 60 or 200 doses, ATC R03AC02)
- LOT 9: Budesonide 0,5 mg/ml (2 ml nebuliser suspension per respule, ATC R03BA02)
- LOT 10: Ciprofloxacin 2 mg/ml (100-200 ml per vial/ampoule, i.v., ATC J01MA02)
- LOT 11: Streptomycin 1 g per vial/ampoule, i.m. (ATC J01GA01)
- LOT 12: Meropenem 500-1000 mg per vial/ampoule, i.v. (ATC J01DH02)
- LOT 13: Clindamycin 600 mg / 4 ml (4 ml per vial/ampoule, i.m. and i.v., ATC J01FF01)
- LOT 14: Ciprofloxacin 250-500 mg per tablet/capsule, oral (ATC J01MA02)
- LOT 15: Ethanol 95-96 % (5-20 ml per vial/ampoule, i.v., ATC V03AB16)
The minimum requirements for the products is described in Annex 1.1.
The Contract will be awarded to one Supplier for each lot based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
The contract period shall enter into force once the contract has been signed by Contracting parties and expires when all contractual duties of the Contract have been performed.
Estimated quantity for the products is described in Annex 6 (restricted to security classification level IV, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Supplier is not obliged to deliver the products under the Option.
Please note that all times given in the Call for tenders refer to local time in Finland.
Call for tenders, Annexes:
Annex 1 Scope of the procurement
Annex 1.1 Minimum requirements
Annex 2 Contract
Annex 3 Security annex
Annex 4 JYSE 2014 SUPPLIES (updated version of April 2022)
Annex 5 Confidentiality commitment
Annex 6 Estimated quantity (restricted, TL IV)
Please note that the numbering of the annexes differs between the Contract and the Call for tenders.
Näytä lisää
Sopimustyyppi: Tavarat
Tuotteet/palvelut: Farmaseuttiset tuotteet📦
Suorituspaikkaa koskevat rajoitukset: Missä tahansa tietyn maan alueella
Tietoa eristä
Tämä sopimus on jaettu osiin ✅
Yhdelle tarjoajalle myönnettävien erien enimmäismäärä: 15
Tarjouksia voidaan jättää enintään yhtä erää varten: 15
1️⃣
Sisäinen tunniste: 1
Otsikko: LOT 1: Morphine 10-20 mg/ml (1-5 ml per vial/ampoule, i.m., ATC N02AA01)
Tämä hankinta soveltuu myös pienille ja keskisuurille yrityksille (pk-yrityksille) ✅
Hankinnan kuvaus:
“The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Morphine 10-20 mg/ml (1-5 ml per...”
Hankinnan kuvaus
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Morphine 10-20 mg/ml (1-5 ml per vial/ampoule, i.m., ATC N02AA01)
- Intramuscular administration
- Active pharmaceutical ingredient: Morphine
- Strength: 10-20 mg/ml
- Pharmaceutical form: 1-5 ml per vial/ampoule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Näytä lisää
Sopimustyyppi: Tavarat
Tuotteet/palvelut: Analgeetit📦
Lisätuotteet/palvelut: Farmaseuttiset tuotteet📦
Maa: Suomi 🇫🇮
Kesto: 13 (MONTH)
Jäljempänä oleva aikataulu on ilmaistu kuukausina.
Tietoa vaihtoehdoista
Vaihtoehdot ✅
Vaihtoehtojen kuvaus:
“In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred...”
Vaihtoehtojen kuvaus
In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
Näytä lisää Myöntämisperusteet
Hinta ✅
Laatukriteeri (nimi): Quality 1: Registered shelf life of the product
Quality 2: Delivery time to the customer’s warehouse
Quality 3: Language of packaging and product information leaflet
Quality 4: Transportation temperature and excursions
Otsikko
Erän tunnistenumero: LOT-0001
2️⃣
Sisäinen tunniste: 2
Otsikko: LOT 2: Ondansetron 2 mg/ml (2-4 ml per vial/ampoule, i.m. and i.v., ATC A04AA01)
Hankinnan kuvaus:
“The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Ondansetron 2 mg/ml (2-4 ml per...”
Hankinnan kuvaus
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Ondansetron 2 mg/ml (2-4 ml per vial/ampoule, i.m. and i.v., ATC A04AA01)
- Intramuscular administration and intravenous administration
- Active pharmaceutical ingredient: Ondansetron
- Strength: 2 mg/ml
- Pharmaceutical form: 2-4 ml per vial/ampoule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
3️⃣
Sisäinen tunniste: 3
Otsikko: LOT 3: Ondansetron 4-8 mg per tablet/capsule, oral (ATC A04AA01)
Hankinnan kuvaus:
“The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Ondansetron 4-8 mg per tablet/capsule,...”
Hankinnan kuvaus
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Ondansetron 4-8 mg per tablet/capsule, oral (ATC A04AA01)
- Oral solid dosage form
- Active pharmaceutical ingredient: Ondansetron
- Strength: 4-8 mg per tablet/capsule
- Pharmaceutical form: tablet/capsule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
4️⃣
Sisäinen tunniste: 4
Otsikko: LOT 4: Hydrocortisone 250 mg / 2 ml (2 ml per vial/ampoule i.v., ATC H02AB09)
Hankinnan kuvaus:
“The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Hydrocortisone 250 mg / 2 ml (2 ml per...”
Hankinnan kuvaus
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Hydrocortisone 250 mg / 2 ml (2 ml per vial/ampoule i.v., ATC H02AB09)
- Powder for solution,, intravenous administration
- Active pharmaceutical ingredient: Hydrocortisone
- Strength: 250 mg / 2 ml
- Pharmaceutical form: 2 ml per vial/ampoule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
5️⃣
Sisäinen tunniste: 5
Otsikko: LOT 5: Epinephrine (Adrenaline) 1 mg/ml (1-5 ml per vial/ampoule, i.v. and i.m., ATC C01CA24)
Hankinnan kuvaus:
“The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Epinephrine (Adrenaline) 1 mg/ml (1-5 ml...”
Hankinnan kuvaus
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Epinephrine (Adrenaline) 1 mg/ml (1-5 ml per vial/ampoule, i.v. and i.m., ATC C01CA24)
- Intravenous administration and intramuscular administration
- Active pharmaceutical ingredient: Epinephrine (Adrenaline)
- Strength: 1 mg/ml
- Pharmaceutical form: 1-5 ml per vial/ampoule, the label shall include inhaling use in addition
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
6️⃣
Sisäinen tunniste: 6
Otsikko: LOT 6: Diazepam 10 mg / 2 ml (2 ml per vial/ampoule, i.m. and i.v., ATC N05BA01)
Hankinnan kuvaus:
“The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Diazepam 10 mg / 2 ml (2 ml per...”
Hankinnan kuvaus
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Diazepam 10 mg / 2 ml (2 ml per vial/ampoule, i.m. and i.v., ATC N05BA01)
- Intramuscular administration and intravenous administration
- Active pharmaceutical ingredient: Diazepam
- Strength: 10 mg / 2 ml
- Pharmaceutical form: 2 ml per vial/ampoule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
7️⃣
Sisäinen tunniste: 7
Otsikko: LOT 7: Midazolam 1-5 mg/ml (3-10 ml per vial/ampoule, i.v., ATC N05CD08)
Hankinnan kuvaus:
“The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Midazolam 1-5 mg/ml (3-10 ml per...”
Hankinnan kuvaus
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Midazolam 1-5 mg/ml (3-10 ml per vial/ampoule, i.v., ATC N05CD08)
- Intravenous administration
- Active pharmaceutical ingredient: Midazolam
- Strength: 1-5 mg/ml
- Pharmaceutical form: 3-10 ml per vial/ampoule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
8️⃣
Sisäinen tunniste: 8
Otsikko: LOT 8: Salbutamol 200 µg/dose (inhaler, 60 or 200 doses, ATC R03AC02)
Hankinnan kuvaus:
“The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Salbutamol 200 µg/dose (inhaler, 60 or...”
Hankinnan kuvaus
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Salbutamol 200 µg/dose (inhaler, 60 or 200 doses, ATC R03AC02)
- Inhalation
- Active pharmaceutical ingredient: Salbutamol
- Strength: 200 µg/dose
- Pharmaceutical form: 60 or 200 doses per inhaler
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
9️⃣
Sisäinen tunniste: 9
Otsikko: LOT 9: Budesonide 0,5 mg/ml (2 ml nebuliser suspension per respule, ATC R03BA02)
Hankinnan kuvaus:
“The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Budesonide 0,5 mg/ml (2 ml nebuliser...”
Hankinnan kuvaus
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Budesonide 0,5 mg/ml (2 ml nebuliser suspension per respule, ATC R03BA02)
- Inhalation
- Active pharmaceutical ingredient: Budesonide
- Strength: 0,5 mg/ml
- Pharmaceutical form: 2 ml nebuliser suspension per respule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
1️⃣0️⃣
Sisäinen tunniste: 10
Otsikko: LOT 10: Ciprofloxacin 2 mg/ml (100-200 ml per vial/ampoule, i.v., ATC J01MA02)
Hankinnan kuvaus:
“The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Ciprofloxacin 2 mg/ml (100-200 ml per...”
Hankinnan kuvaus
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Ciprofloxacin 2 mg/ml (100-200 ml per vial/ampoule, i.v., ATC J01MA02)
- Intravenous administration
- Active pharmaceutical ingredient: Ciprofloxacin
- Strength: 2 mg/ml
- Pharmaceutical form: 100-200 ml per vial/ampoule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
1️⃣1️⃣
Sisäinen tunniste: 11
Otsikko: LOT 11: Streptomycin 1 g per vial/ampoule, i.m. (ATC J01GA01)
Hankinnan kuvaus:
“The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Streptomycin 1 g per vial/ampoule, i.m....”
Hankinnan kuvaus
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Streptomycin 1 g per vial/ampoule, i.m. (ATC J01GA01)
- Powder for solution, intramuscular administration
- Active pharmaceutical ingredient: Streptomycin
- Strength: 1 g per vial/ampoule
- Pharmaceutical form: vial/ampoule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Näytä lisää Myöntämisperusteet
Laatukriteeri (nimi): Reference price
Otsikko
Erän tunnistenumero: LOT-0011
1️⃣2️⃣
Sisäinen tunniste: 12
Otsikko: LOT 12: Meropenem 500-1000 mg per vial/ampoule, i.v. (ATC J01DH02)
Hankinnan kuvaus:
“The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Meropenem 500-1000 mg per vial/ampoule,...”
Hankinnan kuvaus
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Meropenem 500-1000 mg per vial/ampoule, i.v. ( ATC J01DH02)
- Powder for solution, intravenous administration
- Active pharmaceutical ingredient: Meropenem
- Strength: 500-1000 mg per vial/ampoule
- Pharmaceutical form: vial/ampoule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
1️⃣3️⃣
Sisäinen tunniste: 13
Otsikko: LOT 13: Clindamycin 600 mg / 4 ml (4 ml per vial/ampoule, i.m. and i.v., ATC J01FF01)
Hankinnan kuvaus:
“The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Clindamycin 600 mg / 4 ml (4 ml per...”
Hankinnan kuvaus
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Clindamycin 600 mg / 4 ml (4 ml per vial/ampoule, i.m. and i.v., ATC J01FF01)
- Intramuscular administration and intravenous administration
- Active pharmaceutical ingredient: Clindamycin
- Strength: 600 mg / 4 ml
- Pharmaceutical form: 4 ml per vial/ampoule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
1️⃣4️⃣
Sisäinen tunniste: 14
Otsikko: LOT 14: Ciprofloxacin 250-500 mg per tablet/capsule, oral (ATC J01MA02)
Hankinnan kuvaus:
“The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Ciprofloxacin 250-500 mg per...”
Hankinnan kuvaus
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Ciprofloxacin 250-500 mg per tablet/capsule, oral (ATC J01MA02)
- Oral solid dosage form
- Active pharmaceutical ingredient: Ciprofloxacin
- Strength: 250-500 mg per tablet/capsule
- Pharmaceutical form: tablet/capsule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
1️⃣5️⃣
Sisäinen tunniste: 15
Otsikko: LOT 15: Ethanol 95-96 % (5-20 ml per vial/ampoule, i.v., ATC V03AB16)
Hankinnan kuvaus:
“The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Ethanol 95-96 % (5-20 ml per...”
Hankinnan kuvaus
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Ethanol 95-96 % (5-20 ml per vial/ampoule, i.v., ATC V03AB16)
- Intravenous administration
- Active pharmaceutical ingredient: Ethanol
- Strength: 95-96 %
- Pharmaceutical form: 5-20 ml per vial/ampoule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Menettely Toimenpiteen tyyppi
Avoin menettely ✅
Oikeusperusta: Direktiivi 2014/24/EU
Menettelyn tärkeimmät piirteet:
“Tenders must be submitted electronically via the Cloudia Supplier Portal. It is the responsibility of the tenderer to submit the tender by the deadline. No...”
Menettelyn tärkeimmät piirteet
Tenders must be submitted electronically via the Cloudia Supplier Portal. It is the responsibility of the tenderer to submit the tender by the deadline. No compensation will be paid for submitting a tender.
Requirements concerning tenderers and the Article, as well as eventual reports and explanations required in the tender, are described in this Call for tenders.
All the attachments mentioned in the Call for tenders should be sent with the tender. The tender must be submitted in writing, in English. Also, the annexes and all related material or correspondence must be in English.
The process steps are:
1. Opening the tenders.
2. Inspecting the suitability of tenderers according to the ESPD form.
3. Inspecting that tenders meet the requirements set in the Call for tenders.
4. Comparison of tenders.
5. Making and announcing the contract award decision.
6. Verifying the information given by the awarded tenderer on the ESPD form.
7. Background check by asking the winning tenderer to submit criminal record excerpts.
8. Drafting the Contract. The Contract is only valid after a written agreement is signed.
The Contract can be signed no earlier than 14 days from the time the tenderer has been informed, or is considered to have been informed, of the contract award decision and its grounds (=stand-still period).
Näytä lisää Hallinnolliset tiedot
Tarjousten tai osallistumishakemusten vastaanottamisen määräaika: 2024-04-26 12:00:00 📅
Tarjousten avaamista koskevat ehdot: 2024-04-26 12:30:00 📅
Kielet, joilla tarjoukset tai osallistumishakemukset voidaan jättää: englanti 🗣️
Vähimmäisaika, jonka kuluessa tarjoajan on pidettävä tarjous voimassa: 6
Tarjouspyynnön ehdot
Tarjoaja voi jättää useamman kuin yhden tarjouksen
Tarjousten avaamisen päivämäärä: 2024-04-26 12:30:00 📅
Kielet, joilla tarjoukset tai osallistumishakemukset voidaan jättää: englanti 🗣️
Sähköinen laskutus: Pakollinen
Sähköistä maksua käytetään ✅
Lisätietojen pyytämisen määräaika: 2024-04-12 12:00:00 📅
Sopimukseen sisältyy suoritusehtoja ✅
Salassapitosopimus on pakollinen ✅
Oikeudelliset, taloudelliset, rahoitukselliset ja tekniset tiedot Taloudellinen ja rahoituksellinen asema
Luettelo ja lyhyt kuvaus valintaperusteista:
“Yearly turnover: Its (“general”) yearly turnover is as follows:
Year 2022: 1000000,00 EUR
Year 2021: 1000000,00 EUR” Osallistumisehdot
Luettelo ja lyhyt kuvaus olosuhteista:
“Enrolment in a trade register: It is enrolled in the relevant trade registers kept in the Member State of its establishment.” Sopimukseen liittyvät ehdot
Sopimuksen täytäntöönpanoehdot:
“For further details please see the documents of the Call for tenders.” Osallistumisehdot
Poissulkemisperuste: bankr-nat
bankruptcy
corruption
cred-arran
crime-org
distorsion
envir-law
finan-laund
fraud
human-traffic
insolvency
labour-law
liq-admin
misrepresent
nati-ground
partic-confl
prep-confl
prof-misconduct
sanction
socsec-law
socsec-pay
susp-act
tax-pay
terr-offence
Kuvaus poissulkemisperusteista:
“The economic operator is in any analogous situation like bankruptcy arising from a similar procedure under national laws and regulations.”
“The economic operator is bankrupt.” Näytä lisää (22) “The economic operator itself or any person who is a member of its administrative, management or supervisory body or has powers of representation, decision...”
Kuvaus poissulkemisperusteista
The economic operator itself or any person who is a member of its administrative, management or supervisory body or has powers of representation, decision or control therein has been the subject of a conviction by final judgment for corruption, by a conviction rendered at the most five years ago or in which an exclusion period set out directly in the conviction continues to be applicable.
“The economic operator is in arrangement with creditors.”
“The economic operator itself or any person who is a member of its administrative, management or supervisory body or has powers of representation, decision...”
Kuvaus poissulkemisperusteista
The economic operator itself or any person who is a member of its administrative, management or supervisory body or has powers of representation, decision or control therein has been the subject of a conviction by final judgment for participation in a criminal organisation, by a conviction rendered at the most five years ago or in which an exclusion period set out directly in the conviction continues to be applicable.
“The economic operator has entered into agreements with other economic operators aimed at distorting competition.”
“The economic operator has breached its obligations in the field of environmental law.”
“The economic operator itself or any person who is a member of its administrative, management or supervisory body or has powers of representation, decision...”
Kuvaus poissulkemisperusteista
The economic operator itself or any person who is a member of its administrative, management or supervisory body or has powers of representation, decision or control therein has been the subject of a conviction by final judgment for money laundering or terrorist financing, by a conviction rendered at the most five years ago or in which an exclusion period set out directly in the conviction continues to be applicable.
“The economic operator itself or any person who is a member of its administrative, management or supervisory body or has powers of representation, decision...”
Kuvaus poissulkemisperusteista
The economic operator itself or any person who is a member of its administrative, management or supervisory body or has powers of representation, decision or control therein has been the subject of a conviction by final judgment for fraud, by a conviction rendered at the most five years ago or in which an exclusion period set out directly in the conviction continues to be applicable.
“The economic operator itself or any person who is a member of its administrative, management or supervisory body or has powers of representation, decision...”
Kuvaus poissulkemisperusteista
The economic operator itself or any person who is a member of its administrative, management or supervisory body or has powers of representation, decision or control therein has been the subject of a conviction by final judgment for child labour and other forms of trafficking in human beings, by a conviction rendered at the most five years ago or in which an exclusion period set out directly in the conviction continues to be applicable.
“The economic operator is the subject of insolvency or winding-up.”
“The economic operator has breached its obligations in the field of labour law.”
“The assets of the economic operator are being administered by a liquidator or by the court.”
“The economic operator can confirm that:
a) It has been guilty of serious misrepresentation in supplying the information required for the verification of...”
Kuvaus poissulkemisperusteista
The economic operator can confirm that:
a) It has been guilty of serious misrepresentation in supplying the information required for the verification of the absence of grounds for exclusion or the fulfilment of the selection criteria,
b) It has withheld such information,
c) It has not been able, without delay, to submit the supporting documents required by a contracting authority or contracting entity, and
d) It has undertaken to unduly influence the decision making process of the contracting authority or contracting entity, to obtain confidential information that may confer upon it undue advantages in the procurement procedure or to negligently provide misleading information that may have a material influence on decisions concerning exclusion, selection or award.
“Any person who is a member of the economic operator’s administrative, management or supervisory body or has powers of representation, decision or control...”
Kuvaus poissulkemisperusteista
Any person who is a member of the economic operator’s administrative, management or supervisory body or has powers of representation, decision or control therein has been the subject of a conviction by final judgment for work safety offence, working hours offence, work discrimination, extortionate work discrimination, violation of the right to organise or unauthorised use of foreign labour.
“The economic operator is aware of any conflict of interest, as indicated in national law, the relevant notice or the procurement documents due to its...”
Kuvaus poissulkemisperusteista
The economic operator is aware of any conflict of interest, as indicated in national law, the relevant notice or the procurement documents due to its participation in the procurement procedure.
“The economic operator or an undertaking related to it has advised the contracting authority or contracting entity or otherwise been involved in the...”
Kuvaus poissulkemisperusteista
The economic operator or an undertaking related to it has advised the contracting authority or contracting entity or otherwise been involved in the preparation of the procurement procedure.
“The economic operator is guilty of grave professional misconduct.”
“The economic operator has experienced that a prior public contract, a prior contract with a contracting entity or a prior concession contract was terminated...”
Kuvaus poissulkemisperusteista
The economic operator has experienced that a prior public contract, a prior contract with a contracting entity or a prior concession contract was terminated early, or that damages or other comparable sanctions were imposed in connection with that prior contract.
“The economic operator has breached its obligations in the field of social law.”
“The economic operator has breached its obligations relating to the payment social security contributions, both in the country in which it is established and...”
Kuvaus poissulkemisperusteista
The economic operator has breached its obligations relating to the payment social security contributions, both in the country in which it is established and in Member State of the contracting authority or contracting entity if other than the country of establishment.
“The business activities of the economic operator are suspended.”
“The economic operator has breached its obligations relating to the payment of taxes, both in the country in which it is established and in Member State of...”
Kuvaus poissulkemisperusteista
The economic operator has breached its obligations relating to the payment of taxes, both in the country in which it is established and in Member State of the contracting authority or contracting entity if other than the country of establishment.
“The economic operator itself or any person who is a member of its administrative, management or supervisory body or has powers of representation, decision...”
Kuvaus poissulkemisperusteista
The economic operator itself or any person who is a member of its administrative, management or supervisory body or has powers of representation, decision or control therein has been the subject of a conviction by final judgment for terrorist offences or offences linked to terrorist activities, by a conviction rendered at the most five years ago or in which an exclusion period set out directly in the conviction continues to be applicable.
Hankintaviranomainen Nimi ja osoitteet
Nimi: Finnish Institute for Health and Welfare
Kansallinen rekisterinumero: 2229500-6
Postiosoite: P. O. BOX 30
Postinumero: 00271
Postitoimipaikka: Helsinki
Alue: Helsinki-Uusimaa🏙️
Maa: Suomi 🇫🇮
Yhteyspiste: Procurement services / Keskitetty hankintatoimi
Sähköposti: kilpailutus@thl.fi📧
Puhelin: +358 295246000📞
URL: https://thl.fi/en/web/thlfi-en🌏 Hankintaviranomaisen tyyppi
Ministeriö tai muu kansallinen tai liittovaltiotason viranomainen
Päätoimi
Terveys
Viestintä
Osallistumisen URL-osoite: https://tarjouspalvelu.fi/thl?id=501558&tpk=d87e90c6-b2c9-4c6c-9a33-53ba2cd58f6b🌏
EU:n rahoituksen tunniste: rescEU-CBRNSTOCK-FI
Lisätietoa EU-rahoituksesta:
“rescEU - CBRN Stockpiling in Finland”
EU:n rahoitusohjelma: Unionin pelastuspalvelumekanismi (rescEU) (2021/2027)
Perustelut tiettyjen hankinta-asiakirjojen saatavuuden rajoittamiselle: Erityisen arkaluonteisten tietojen suojaaminen
Hankinta-asiakirjoihin pääsyä on rajoitettu
Hankinta-asiakirjan kieli: englanti 🗣️
Tarjouksen/hakemuksen jättäminen sähköisesti: Pakollinen
Täydentävät tiedot Lisätietoja
“The availability for the Annex 6 is restricted to security classification level IV (TL IV). THL will send the Annex 6 to a representative of the tenderer...”
Lisätietoja
The availability for the Annex 6 is restricted to security classification level IV (TL IV). THL will send the Annex 6 to a representative of the tenderer via encrypted e-mail after THL has received a scanned version of the signed confidentiality commitment (Annex 5). The signature of the confidentiality commitment shall be done manually by hand. Confidentiality commitment shall be signed by a legal representative of tenderer. Confidentiality commitment shall be sent to the e-mail address kirjaamo@thl.fi with the subject line "CONFIDENTIALITY COMMITMENT - THL/1198/2.02.06/2024 / Various pharmaceutical products". The message shall contain name of the tenderer and e-mail address to which the Annex 6 is to be sent.
Näytä lisää Arvostelurunko
Nimi: Markkinaoikeus
Kansallinen rekisterinumero: 3006157-6
Postiosoite: Radanrakentajantie 5
Postinumero: 00520
Postitoimipaikka: Helsinki
Alue: Helsinki-Uusimaa🏙️
Maa: Suomi 🇫🇮
Sähköposti: markkinaoikeus@oikeus.fi📧
Puhelin: +358 295643300📞
URL: http://www.oikeus.fi/markkinaoikeus🌏 Tietoa sähköisistä työnkuluista
Sähköinen laskutus hyväksytään
Sähköistä maksua käytetään
Lähde: OJS 2024/S 060-175216 (2024-03-22)
Muutokset Alkuperäiseen ilmoitukseen korjattava teksti
Erän tunnistenumero: LOT-0001
LOT-0002
LOT-0003
LOT-0004
LOT-0005
LOT-0006
LOT-0007
LOT-0008
Uusi arvo
Teksti:
“Award criterion 1
Original:
The reference price of the tender consists of the total price of the offered Articles. The total price shall be based on the...”
Teksti
Award criterion 1
Original:
The reference price of the tender consists of the total price of the offered Articles. The total price shall be based on the quantity of single units (tablets, vials etc.) that is needed to comply with the announced active pharmaceutical ingredient (API) total quantity described in the Annex 6 (Estimated quantity, TL IV). The offered price includes the Articles and transport according to the call for tenders and covers all requirements set out in the Call for Tenders and it's Annexes.
Corrected:
The reference price of the tender consists of the total price of the offered Articles. The total price shall be based on the quantity of single units (inhaler) that is needed to comply with the announced total quantity of doses described in the Annex 6 (Estimated quantity, TL IV). The offered price includes the Articles and transport according to the call for tenders and covers all requirements set out in the Call for Tenders and it's Annexes.
Näytä lisää Alkuperäiseen ilmoitukseen korjattava teksti
Erän tunnistenumero: LOT-0009
LOT-0010
LOT-0011
LOT-0012
LOT-0013
LOT-0014
LOT-0015
Uusi arvo
Teksti:
“Award criteria 1
Original:
The reference price of the tender consists of the total price of the offered Articles. The total price shall be based on the...”
Teksti
Award criteria 1
Original:
The reference price of the tender consists of the total price of the offered Articles. The total price shall be based on the quantity of single units (tablets, vials etc.) that is needed to comply with the announced active pharmaceutical ingredient (API) total quantity described in the Annex 6 (Estimated quantity, TL IV). The offered price includes the Articles and transport according to the call for tenders and covers all requirements set out in the Call for Tenders and it's Annexes.
Corrected:
The reference price of the tender consists of the total price of the offered Articles. The total price shall be based on the quantity of single units (vial/ampoule) that is needed to comply with the announced total volume described in the Annex 6 (Estimated quantity, TL IV). The offered price includes the Articles and transport according to the call for tenders and covers all requirements set out in the Call for Tenders and it's Annexes.
“The contracting entity has incorrectly indicated the formation of the reference price for lot 8 and lot 15. As an exception to the other lots, the reference...”
Muut lisätiedot
The contracting entity has incorrectly indicated the formation of the reference price for lot 8 and lot 15. As an exception to the other lots, the reference price for subdivisions 8 and 15 is not based on the quantity of active pharmaceutical ingredient (API). For lot 8, the reference price is constructed based on the total quantity of doses, and for lot 15, the reference price is constructed based on the total volume of the Article. The total quantities of Articles are correctly indicated in the original Annex 6 Estimated quantity (restricted, TL IV).
Due to this correction, the deadline for receiving tenders will be extended and the deadline for questions related to the procurement will be extended.
Näytä lisää
Muutoksen pääasiallinen syy: Ostajan virheen korjaaminen
Information about modifications
Muutettavan ilmoituksen edellinen versio: 13d4017b-a0a2-4f28-973e-4e178ec3e6e8-01
Lähde: OJS 2024/S 074-220755 (2024-04-12)